United States Últimas notícias

Greenwich LifeSciences (NASDAQ:GLSI) reported new open-label immune response data from its ongoing Phase III FLAMINGO-01 clinical trial evaluating its lead immunotherapy candidate, GLSI-100, in patients with HER2-positive breast cancer.

Rallybio (NASDAQ:RLYB) and Avenzo Therapeutics announced Monday that they have entered into a definitive agreement to combine through a merger transaction.

Rocky Mountain Chocolate Factory (NASDAQ:RMCF) reported its financial and operating results for the fiscal fourth quarter and full year ended February 28, 2026, revealing a planned contraction in lower-margin sales alongside structural improvements in its underlying expense profile and product profit margins.

SOLAI (NYSE:SLAI) has reached an agreement to acquire a controlling interest in a Singaporean artificial intelligence developer, accelerating its corporate pivot away from cryptocurrency mining operations toward an AI-first infrastructure platform.

ParaZero Technologies (NASDAQ:PRZO) has secured its first commercial order from an unnamed U.S.-based Tier-1 defense corporation for its proprietary DefendAir Net Pods.

Welltower (NYSE:WELL) has announced that it expects to increase its quarterly common dividend by 15% to $0.85 per share, beginning with the second quarter of 2026.

AstraZeneca (NASDAQ:AZN) unveiled positive data from its late-stage EMERALD-3 clinical trial on Monday, demonstrating that adding its dual-immunotherapy regimen to standard localized therapy significantly slows disease progression in patients battling early-stage, unresectable liver cancer.

Kamada (NASDAQ:KMDA) announced Monday that the U.S. Food and Drug Administration has approved its new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) rabies virus neutralization laboratory at its manufacturing plant in Beit Kama, Israel.

Torsten Slok, chief economist at Apollo, explains what people are getting wrong about the impact of AI on the US labor market.

Marex Group (NASDAQ:MRX) announced Monday that it has acquired Levmet, a Monaco-based liquidity provider, in a move to strengthen its physical market-making operations and secure a firmer foothold in European power and gas trading.

Jade Biosciences (NASDAQ:JBIO) delivered a significant milestone for its autoimmune pipeline, reporting positive interim results from its Phase 1 clinical trial evaluating JADE101.

Monopar Therapeutics (NASDAQ:MNPR) announced encouraging mid-stage clinical results for its investigational Wilson disease therapy, demonstrating widespread stabilization in liver pathology alongside substantial neurological and quality-of-life improvements.